Fzata is a near-clinical-stage, multi-asset platform company developing a new class of oral biologics using proprietary bioengineered probiotic yeast medicines (BioPYM). By enabling needle-free delivery, eliminating cold-chain requirements, and localizing to the gut, BioPYM has the potential to expand access, reduce cost, and improve patient adherence across large immunology and gastrointestinal markets.

​

Fzata’s pipeline is led by FZ002 for Clostridioides difficile infection, on track for IND submission in May 2026 with NIH sponsoring, and FZ006, an oral anti-TNFα therapy for inflammatory bowel disease targeting both biologics-experienced and earlier-stage patients. With a streamlined, fermentation-based manufacturing process and a modular, plug-and-play discovery platform, Fzata is positioned to advance multiple programs efficiently as it prepares for Series A financing.